Do analysts prefer BKHA or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BKHA or BLRX?

Black Hawk Acquisition has higher earnings, but lower revenue than BioLineRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A BioLineRx $1.18M 10.24 -$1.17M -$1.69 N/A

Do analysts recommend TVGN or BLRX?

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 1,218.39%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVGN or BLRX more profitable?

Tevogen Bio has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. Tevogen Bio's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% BioLineRx -502.08% -34.80% -18.27%

Do analysts rate HOWL or BLRX?

Werewolf Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 314.94%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ATYR or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ATYR or BLRX?

BioLineRx has higher revenue and earnings than aTyr Pharma. BioLineRx is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 202.89 -$74.12M -$0.62 N/A BioLineRx $1.18M 10.24 -$1.17M -$1.69 N/A

Is ATYR or BLRX more profitable?

aTyr Pharma has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% BioLineRx -502.08% -34.80% -18.27%

Do analysts rate BLRX or EDSA?

Edesa Biotech has a consensus price target of $5.00, suggesting a potential upside of 29.03%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is BLRX or EDSA more profitable?

Edesa Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -502.08% -34.80% -18.27% Edesa Biotech N/A -560.22% -105.74%

BioLineRx (BLRX) Competitors

$2.49 +0.01 (+0.48%)

As of 09:44 AM Eastern

Compare

BLRX vs. BKHA, TVGN, HOWL, ATYR, and EDSA

Should you buy BioLineRx stock or one of its competitors? BioLineRx's main competitors and comparable companies include Black Hawk Acquisition (BKHA), Tevogen Bio (TVGN), Werewolf Therapeutics (HOWL), aTyr Pharma (ATYR), and Edesa Biotech (EDSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioLineRx compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Hawk Acquisition has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Black Hawk Acquisition has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. Black Hawk Acquisition's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
BioLineRx	-502.08%	-34.80%	-18.27%

1.6% of BioLineRx shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Black Hawk Acquisition had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Black Hawk Acquisition and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.74 beat Black Hawk Acquisition's score of 0.44 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Black Hawk Acquisition	Neutral
BioLineRx	Positive

Black Hawk Acquisition has higher earnings, but lower revenue than BioLineRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
BioLineRx	$1.18M	10.24	-$1.17M	-$1.69	N/A

Summary

BioLineRx beats Black Hawk Acquisition on 5 of the 9 factors compared between the two stocks.

How does BioLineRx compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

1.6% of BioLineRx shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 1,218.39%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tevogen Bio has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. Tevogen Bio's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
BioLineRx	-502.08%	-34.80%	-18.27%

Tevogen Bio has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

In the previous week, Tevogen Bio and Tevogen Bio both had 1 articles in the media. Tevogen Bio's average media sentiment score of 1.87 beat BioLineRx's score of 0.74 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Very Positive
BioLineRx	Positive

BioLineRx has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
BioLineRx	$1.18M	10.24	-$1.17M	-$1.69	N/A

Summary

BioLineRx beats Tevogen Bio on 7 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Werewolf Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Werewolf Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
BioLineRx	-502.08%	-34.80%	-18.27%

In the previous week, Werewolf Therapeutics had 2 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.74 beat Werewolf Therapeutics' score of 0.22 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
BioLineRx	Positive

BioLineRx has lower revenue, but higher earnings than Werewolf Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	24.92	-$60.82M	-$0.76	N/A
BioLineRx	$1.18M	10.24	-$1.17M	-$1.69	N/A

Werewolf Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 314.94%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Werewolf Therapeutics beats BioLineRx on 11 of the 16 factors compared between the two stocks.

How does BioLineRx compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

aTyr Pharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

aTyr Pharma has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
BioLineRx	-502.08%	-34.80%	-18.27%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, aTyr Pharma had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for aTyr Pharma and 1 mentions for BioLineRx. aTyr Pharma's average media sentiment score of 0.94 beat BioLineRx's score of 0.74 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Positive
BioLineRx	Positive

BioLineRx has higher revenue and earnings than aTyr Pharma. BioLineRx is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	202.89	-$74.12M	-$0.62	N/A
BioLineRx	$1.18M	10.24	-$1.17M	-$1.69	N/A

Summary

aTyr Pharma beats BioLineRx on 11 of the 16 factors compared between the two stocks.

How does BioLineRx compare to Edesa Biotech?

BioLineRx (NASDAQ:BLRX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

BioLineRx has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Edesa Biotech has a consensus price target of $5.00, suggesting a potential upside of 29.03%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

BioLineRx has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.24	-$1.17M	-$1.69	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

Edesa Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
Edesa Biotech	N/A	-560.22%	-105.74%

In the previous week, BioLineRx and BioLineRx both had 1 articles in the media. Edesa Biotech's average media sentiment score of 1.27 beat BioLineRx's score of 0.74 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLineRx	Positive
Edesa Biotech	Positive

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Edesa Biotech beats BioLineRx on 8 of the 14 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.78M	$3.84B	$7.22B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-1.56	14.33	273.84	25.33
Price / Sales	10.24	1,390.29	637.14	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	0.46	15.23	10.36	6.24
Net Income	-$1.17M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-3.04%	-2.52%	-0.83%	-1.20%
1 Month Performance	-5.61%	-2.86%	-1.36%	-4.26%
1 Year Performance	-33.72%	37.92%	21.13%	5.47%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	0.6152 of 5 stars	$2.49 +0.5%	N/A	-36.2%	$12.78M	$1.18M	N/A	40
BKHA Black Hawk Acquisition	N/A	$11.89 -0.9%	N/A	+6.4%	$49.37M	N/A	N/A	N/A
TVGN Tevogen Bio	1.7006 of 5 stars	$7.33 -0.1%	$100.00 +1,264.3%	-81.6%	$47.72M	N/A	N/A	3	Positive News Gap Down
HOWL Werewolf Therapeutics	2.7905 of 5 stars	$0.98 +1.4%	$4.00 +308.2%	-36.6%	$47.63M	$1.88M	N/A	40	Short Interest Increase Gap Down
ATYR aTyr Pharma	0.9857 of 5 stars	$0.48 -3.3%	N/A	-64.4%	$47.16M	$190K	N/A	53

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. BKHA, TVGN, HOWL, ATYR, and EDSA

How does BioLineRx compare to Black Hawk Acquisition?

Summary

How does BioLineRx compare to Tevogen Bio?

Summary

How does BioLineRx compare to Werewolf Therapeutics?

Summary

How does BioLineRx compare to aTyr Pharma?

Summary

How does BioLineRx compare to Edesa Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. BKHA, TVGN, HOWL, ATYR, and EDSA

How does BioLineRx compare to Black Hawk Acquisition?

Do analysts prefer BKHA or BLRX?

Which has more volatility & risk, BKHA or BLRX?

Is BKHA or BLRX more profitable?

Do institutionals & insiders have more ownership in BKHA or BLRX?

Does the media favor BKHA or BLRX?

Which has preferable earnings & valuation, BKHA or BLRX?

Summary

How does BioLineRx compare to Tevogen Bio?

Do insiders and institutionals have more ownership in TVGN or BLRX?

Do analysts recommend TVGN or BLRX?

Is TVGN or BLRX more profitable?

Which has more risk and volatility, TVGN or BLRX?

Does the media prefer TVGN or BLRX?

Which has better earnings & valuation, TVGN or BLRX?

Summary

How does BioLineRx compare to Werewolf Therapeutics?

Do insiders & institutionals hold more shares of HOWL or BLRX?

Which has more volatility & risk, HOWL or BLRX?

Is HOWL or BLRX more profitable?

Does the media prefer HOWL or BLRX?

Which has stronger valuation and earnings, HOWL or BLRX?

Do analysts rate HOWL or BLRX?

Summary

How does BioLineRx compare to aTyr Pharma?

Which has more risk & volatility, ATYR or BLRX?

Do insiders and institutionals hold more shares of ATYR or BLRX?

Is ATYR or BLRX more profitable?

Do analysts prefer ATYR or BLRX?

Does the media prefer ATYR or BLRX?

Which has stronger earnings and valuation, ATYR or BLRX?

Summary

How does BioLineRx compare to Edesa Biotech?

Which has more risk & volatility, BLRX or EDSA?

Do analysts rate BLRX or EDSA?

Which has stronger valuation & earnings, BLRX or EDSA?

Is BLRX or EDSA more profitable?

Does the media refer more to BLRX or EDSA?

Do institutionals & insiders hold more shares of BLRX or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools